{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:53:08Z","timestamp":1781697188195,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with systemic features, characterized by painful nodules, abscesses, and sinus tracts. Pro-inflammatory cytokines may serve as biomarkers of disease severity, inflammatory burden, and therapeutic response. The aim of this article is to systematically review the current evidence on serum concentrations of pro-inflammatory cytokines in patients with HS and to evaluate their potential utility as biomarkers of disease activity and personalized treatment guidance. Materials and Methods: This systematic review was conducted in accordance with the PRISMA 2020 guidelines. A literature search was performed in PubMed, Embase, and Scopus, with Google Scholar used as a supplementary source. The search included English-language publications from 2015 to 2026. The following keywords were used in combination: \u201ccytokines\u201d, \u201cserum\u201d, \u201chidradenitis suppurativa\u201d, and \u201cmarkers\u201d. In addition, reference lists and citations of eligible full-text articles were manually screened. Eligible studies for inclusion were peer-reviewed, original human studies reporting serum cytokine levels in patients with HS. Reviews, meta-analyses, case reports, editorials, letters, in vitro and animal studies, conference abstracts without the full text available, non-serum studies, and thematically unrelated publications were excluded. Results: Database searches identified records in PubMed, Embase, Scopus, and Google Scholar, of which three PubMed studies met the inclusion criteria. Manual screening of reference lists and citations identified three additional eligible publications. Overall, six studies were included in the final qualitative synthesis. The included studies reported elevated serum levels of key inflammatory mediators, including IL-17A, IL-6, IL-1\u03b2, IL-23, IL-18, and soluble TNF receptors, in patients with HS compared to healthy controls. Several cytokines were associated with disease severity, and selected markers showed changes during biologic treatment. Stratification into immunological endotypes based on cytokine profiles and clinical features was also proposed. Conclusions: Pro-inflammatory cytokines, especially those involved in the IL-1\u03b2\u2013IL-17 axis, show potential as biomarkers of disease severity and treatment response in HS. Their assessment may support future personalized therapeutic strategies. However, current evidence remains limited by small study numbers and methodological heterogeneity. Further large-scale prospective and longitudinal studies are required before serum cytokine profiling can be implemented in routine clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15124699","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:19:53Z","timestamp":1781691593000},"page":"4699","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding Inflammation in Hidradenitis Suppurativa: Serum Cytokines as Biomarkers of Disease Severity and Treatment Outcome\u2014Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-6340","authenticated-orcid":false,"given":"Anna","family":"Tekielak","sequence":"first","affiliation":[{"name":"Doctoral School, Medical University of Silesia, 40-055 Katowice, Poland"},{"name":"Department of Dermatology, Medical University of Silesia, Francuska 20\/42, 40-027 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-5427","authenticated-orcid":false,"given":"Karina","family":"Polak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Silesia, Francuska 20\/42, 40-027 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Fr\u0105tczak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Silesia, Francuska 20\/42, 40-027 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Bergler-Czop","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Silesia, Francuska 20\/42, 40-027 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e15179","DOI":"10.1111\/exd.15179","article-title":"Interleukin-1 family cytokines and soluble receptors in hidradenitis suppurativa","volume":"33","author":"Gambino","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_3","first-page":"2450401","article-title":"The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa","volume":"2017","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2340\/00015555-0866","article-title":"Psychophysical aspects of hidradenitis suppurativa","volume":"90","author":"Matusiak","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cyto.2017.12.020","article-title":"Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa","volume":"103","year":"2018","journal-title":"Cytokine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000536268","article-title":"Cytokine-Mediated Molecular Pathophysiology of Hidradenitis Suppurativa: A Narrative Review","volume":"10","author":"Melchor","year":"2024","journal-title":"Skin Appendage Disord."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., and Fabbrocini, G. (2021). Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 10.","DOI":"10.3390\/cells10082094"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Vossen, A.R.J.V., van der Zee, H.H., and Prens, E.P. (2018). Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front Immunol., 9.","DOI":"10.3389\/fimmu.2018.02965"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: Is there a basis for treatment with anti-tumour necrosis factor-alpha agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e139932","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"key":"ref_12","first-page":"e50","article-title":"Decoding the IL-17 axis in hidradenitis suppurativa: Pharmacodynamic profiling of the Nanobody\u00ae sonelokimab reveals IL-19 and PI3 as biomarkers of IL-17 pathway activity, 6th Inflammatory Skin Disease Summit","volume":"145","author":"Krueger","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000511045","article-title":"Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis","volume":"237","author":"Vilarrasa","year":"2021","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jid.2021.02.742","article-title":"In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes","volume":"141","author":"Navrazhina","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Del Duca, E., Morelli, P., Bennardo, L., Di Raimondo, C., and Nistic\u00f2, S.P. (2020). Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228436"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaad.2020.08.084","article-title":"Serum cytokine levels in patients with hidradenitis suppurativa vary with race","volume":"84","author":"McKay","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1177\/12034754241300292","article-title":"Hidradenitis suppurativa: A review of the biologic and small molecule immunomodulatory treatments","volume":"29","author":"Chiang","year":"2025","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/bjd\/ljae442","article-title":"The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: Evidence from human in vitro preclinical experiments and clinical samples","volume":"192","author":"Rastrick","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jid.2025.04.009","article-title":"Differentiating the Role of Inflammation in Hidradenitis Suppurativa from that in other Inflammatory Skin Diseases","volume":"145","author":"Byrd","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/cmi.2010.21","article-title":"Interleukin-17 and its expanding biological functions","volume":"7","author":"Xu","year":"2010","journal-title":"Cell Mol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s13555-025-01462-7","article-title":"Towards a paradigm shift in delivering hidradenitis suppurativa care: A narrative review","volume":"15","author":"Bechara","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jdin.2024.03.002","article-title":"Biomarkers of systemic inflammation are associated with disease severity and metabolic syndrome in patients with hidradenitis suppurativa","volume":"15","author":"Holgersen","year":"2024","journal-title":"JAAD Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"155585","DOI":"10.1016\/j.cyto.2021.155585","article-title":"Serum high-sensitivity C-reactive protein, tumor necrosis factor-\u03b1, interleukin (IL)-1\u03b2, IL-17A and IL-23 levels in patients with hidradenitis suppurativa","volume":"144","author":"Ergun","year":"2021","journal-title":"Cytokine"},{"key":"ref_25","first-page":"9267","article-title":"Evaluation of systemic immune and inflammatory biomarkers in hidradenitis suppurativa","volume":"27","author":"Utlu","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/ajd.12766","article-title":"Hidradenitis suppurativa: A review of pathogenesis, associations and management. Part 2","volume":"59","author":"Vekic","year":"2018","journal-title":"Australas. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zouboulis, V.A., Zouboulis, K.C., and Zouboulis, C.C. (2022). Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug repurposing\u2014A molecular meta-analysis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010044"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.12688\/f1000research.17268.2","article-title":"A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2019","journal-title":"F1000Research"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/bjd\/ljae238","article-title":"Unravelling the complex pathogenesis of hidradenitis suppurativa","volume":"192","author":"Frew","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamadermatol.2019.3412","article-title":"Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa","volume":"156","author":"Reddy","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/bjd.15424","article-title":"Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa\/hidradenitis suppurativa","volume":"177","author":"Wolk","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sabat, R., Chanwangpong, A., Schneider-Burrus, S., Metternich, D., Kokolakis, G., Kurek, A., Philipp, S., Uribe, D., Wolk, K., and Sterry, W. (2012). Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031810"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4699\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:06:58Z","timestamp":1781694418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124699"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124699","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}